Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference
New York, NY – April 7, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 21st Annual Needham Virtual Healthcare Conference
Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March
New York, NY – March 8, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will participate in multiple virtual healthcare investor conferences taking place
Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology
--Drs. Josep Tabernero, M.D., Ph.D. and Alan Venook, M.D. to Support Company in Advancing Pipeline of Novel Drug Candidates Derived from its RNA-DRIVErTM Discovery Platform NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics,
Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST
Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference
New York, NY – November 10, 2021 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Stifel 2021 Virtual Healthcare Conference at
Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104 (abequolixron), the Company’s small molecule